サンプル依頼リスト カート
  • English
デフォルト表紙
市場調査レポート
商品コード
1737517

抗体発見の世界市場

Antibody Discovery

出版日
ページ情報
英文 224 Pages
納期
即日から翌営業日
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=144.08円
抗体発見の世界市場
出版日: 2025年05月30日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 224 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

抗体発見の世界市場は2030年までに33億米ドルに到達

2024年に19億米ドルと推定される抗体発見の世界市場は、2024年から2030年にかけてCAGR 9.8%で成長し、2030年には33億米ドルに達すると予測されます。本レポートで分析したセグメントの一つであるモノクローナル抗体は、CAGR 9.3%を記録し、分析期間終了時には20億米ドルに達すると予想されます。ポリクローナル抗体分野の成長率は、分析期間中CAGR 10.9％と推定されます。

米国市場は5億米ドルと推定、中国はCAGR 9.5%で成長すると予測

米国の抗体発見市場は2024年に5億米ドルと推定されます。世界第2位の経済大国である中国は、2030年までに5億3,070万米ドルの市場規模に達すると予測され、分析期間2024-2030年のCAGRは9.5%です。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ8.9%と8.4%と予測されています。欧州では、ドイツがCAGR 7.9%で成長すると予測されています。

世界の抗体発見市場- 主要動向と促進要因のまとめ

抗体発見が次世代治療薬開発の最前線にある理由とは？

抗体発見は、腫瘍、自己免疫疾患、感染症、希少疾患などの標的治療に対する需要の高まりにより、現代の医薬品開発の要として台頭してきています。モノクローナル抗体（mAbs）、二特異性抗体、抗体薬物複合体（ADC）は、その高い特異性、調整可能な薬物動態、正確な分子標的への関与または阻害能力により、臨床転帰を一変させています。標的の同定、抗体の作製、スクリーニング、リードの最適化を含む探索段階は、下流の治療効果、安全性、商業的実行可能性を確保するために極めて重要です。バイオ医薬品のパイプラインが低分子よりも生物製剤を優先する傾向が強まる中、抗体発見はイノベーションへの不可欠なゲートウェイになりつつあります。

この動向の大きな原動力となっているのは、個別化医療や免疫療法に対する需要の急増であり、抗体ベースの治療薬は、免疫反応の調節、疾患関連経路の遮断、腫瘍細胞への細胞毒性ペイロードの直接導入などに使用されています。COVID-19の大流行がもたらした緊急性は、中和抗体がSARS-CoV-2に対する治療・診断反応において極めて重要であったことから、迅速な抗体発見の重要性をさらに際立たせた。治療用抗体に対する世界の関心の高まりは、製薬会社やバイオテクノロジー企業に、より迅速で、より予測可能で、より免疫原性の低い方法を用いた探索プログラムの加速化を促しています。市場が従来のハイブリドーマ技術からヒト化プラットフォームや次世代インシリコアプローチにシフトする中、抗体発見は世界中のバイオファーマの研究開発戦略の中心に位置しています。

技術革新はどのように創薬期間を短縮し、リードの質を向上させているのか？

最先端技術は、抗体発見プロセスの各段階を再形成し、安全性と製造性に優れた親和性の高い開発可能な抗体をより早く同定することを可能にしています。ファージディスプレイや酵母ディスプレイプラットフォームは、従来のハイブリドーマベースの作製に取って代わり、膨大な多様性ライブラリーと迅速な選択能力を提供しています。さらに最近では、マイクロ流体工学、単一B細胞スクリーニング、ハイスループットシークエンシングが、免疫動物や回復期のヒトドナーから天然に存在する抗体レパートリーを取得することにより、初期段階の探索に革命をもたらしました。これらのツールは、従来の方法では検出されなかったような、希少で非常に強力な抗体の単離を可能にしています。

計算生物学とAI主導のデザインもまた、結合親和性、安定性、免疫原性、エピトープ特異性をインシリコで予測することにより、探索パイプラインを変革しています。機械学習アルゴリズムは、大規模な抗体データセットでトレーニングされ、リード化合物の最適化を加速し、実験の試行錯誤を減らし、その後の開発段階での成功率を向上させています。ヒト化技術は、キメラ化から完全な脱免疫化まで、安全性を高め、拒絶反応のリスクを低減するために改良されています。さらに、CRISPR/Cas9とトランスジェニック動物モデルを活用して、正確な特異性を持つ完全ヒト抗体を作製しています。このような技術の統合により、迅速でスケーラブル、かつコスト効率の高いワークフローが可能になり、規制や治療上の厳格な基準を満たすことができます。

市場の需要はどこで高まり、どの治療分野が創薬への投資を促進しているか？

抗体発見のサービスやプラットフォームに対する市場需要は、北米、欧州、アジア太平洋地域で急増しており、バイオファーマ企業、学術研究所、医薬品開発業務受託機関（CRO）は、抗体ベースのパイプラインを拡大するための取り組みを強化しています。米国は、バイオテクノロジーへの多額の投資、先進的な研究インフラ、迅速な生物学的製剤承認のための規制当局のサポートに支えられ、抗体医薬の開発でリードしています。欧州、特にドイツ、スイス、英国では、CROをベースとした創薬提携やアカデミアのスピンアウトが力強い伸びを示しています。一方、アジア太平洋（特に中国、韓国、日本）は、国が支援するバイオテクノロジープログラム、臨床試験の活発化、迅速な商業化戦略に後押しされ、抗体技術革新の主要拠点となりつつあります。

がん領域は、モノクローナル抗体や二重特異性抗体のパイプラインの大半を占め、依然として抗体発見の最大かつ最も急成長している治療分野です。PD-1/PD-L1、CTLA-4、CD3、CD20のターゲットに多額の投資が行われ、チェックポイント阻害剤やT細胞エンゲージャーなどの免疫腫瘍学への応用が急速に拡大しています。関節リウマチ、乾癬、クローン病などの自己免疫疾患や炎症性疾患も、IL-6、TNF-α、IL-17などのサイトカインや免疫レセプターを標的とした抗体候補が主要な探索領域となっています。感染症研究は、HIV、RSV、インフルエンザをターゲットとした新たなプログラムにより、COVID-19の後も引き続き抗体発見を牽引しています。ALS、アルツハイマー病、視神経脊髄炎を含む希少疾患や神経疾患は、精密抗体治療にとって価値の高いニッチとして台頭してきています。こうした多様で拡大する適応症は、各分野における抗体発見ワークフローへの持続的な投資と技術革新を後押ししています。

抗体発見世界市場の成長を後押ししているのは？

抗体発見市場の成長は、慢性疾患や希少疾患の有病率の上昇、生物製剤パイプラインの拡大、分子スクリーニングやAI支援ドラッグデザインにおけるブレークスルーなど、いくつかの要因によって牽引されています。中心的な促進要因は、トラスツズマブ、アダリムマブ、ペムブロリズマブなど、既に市場に投入されている抗体の治療成功であり、抗体ベースの医薬品の臨床的・商業的可能性を実証し続けています。製薬大手と抗体発見のスペシャリストとの間の活発な取引は、差別化されたプラットフォームや有望な候補化合物への早期アクセスを求める企業によるもので、成長をさらに促進しています。

バイオテクノロジー新興企業や中堅企業によるアウトソーシングの増加は、CROや専門技術ベンダーが抗原設計からヒト化リード化合物の送達までエンドツーエンドの探索能力を提供する、ディスカバリー・アズ・ア・サービス・モデルに対する市場の需要も促進しています。自動化、シークエンシング、データ解析の進歩は、成功の予測可能性を向上させながら、発見あたりのコストを引き下げており、抗体研究開発を中小企業にとってより身近なものにしています。さらに、パンデミック対策、がん免疫療法、バイオシミラー開発のための政府・機関からの資金援助は、官民双方の関与を後押ししています。抗体治療薬が精密医療や免疫調節の中心的存在となるにつれ、重要な疑問が浮かび上がってくきます。抗体発見プラットフォームは、次世代生物学的製剤による治療で必要とされる臨床的複雑性と特異性に対応できるのだろうか？

セグメント

抗体タイプ（モノクローナル、ポリクローナル、その他の抗体タイプ）、サービス（ファージディスプレイ、ハイブリドーマ、その他のサービス）、エンドユーザー（製薬・バイオテクノロジー企業、研究所、その他のエンドユーザー）

調査対象企業の例（合計 41注目）

  • Abcam plc
  • AbCellera Biologics Inc.
  • Ablexis, LLC
  • Adimab LLC
  • Akeso Biopharma
  • Biocytogen Pharmaceuticals Co., Ltd.
  • Bruker Corporation
  • Charles River Laboratories
  • ChemPartner
  • Creative Biolabs
  • Danaher Corporation
  • Eurofins Scientific
  • Evotec SE
  • FairJourney Biologics S.A.
  • Genmab A/S
  • GenScript Biotech Corporation
  • Harbour BioMed
  • Icosagen AS
  • ImmunoPrecise Antibodies Ltd.
  • Isogenica Ltd.

関税影響係数

Global Industry Analystsは、本社の国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、人為的な売上原価の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

Global Industry Analystsは、世界の主要なチーフ・エコノミスト（1万4,949人）、シンクタンク（62団体）、貿易・産業団体（171団体）の専門家の意見に熱心に従いながら、エコシステムへの影響を評価し、新たな市場の現実に対処しています。あらゆる主要国の専門家やエコノミストが、関税とそれが自国に与える影響についての意見を追跡調査しています。

Global Industry Analystsは、この混乱が今後2-3ヶ月で収束し、新しい世界秩序がより明確に確立されると予想しています。Global Industry Analystsは、これらの開発をリアルタイムで追跡しています。

2025年4月：交渉フェーズ

4月のリリースでは、世界市場全体に対する関税の影響を取り上げ、地域別の市場調整について紹介します。当社の予測は、過去のデータと進化する市場影響要因に基づいています。

2025年7月：最終関税リセット

お客様には、各国間で最終リセットが発表された後、7月に無料アップデート版をお届けします。最終アップデート版には、明確に定義された関税影響分析が組み込まれています。

相互および二国間貿易と関税の影響分析：

アメリカ <>中国<>メキシコ <>カナダ <>EU <>日本<>インド <>その他176カ国

業界をリードするエコノミスト：Global Industry Analystsの知識ベースは、国家、シンクタンク、貿易・業界団体、大企業、そして世界の計量経済状況におけるこの前例のないパラダイムシフトの影響を共有する領域の専門家など、最も影響力のあるチーフエコノミストを含む1万4,949人のエコノミストを追跡しています。当社の16,491を超えるレポートのほとんどは、マイルストーンに基づくこの2段階のリリーススケジュールを取り入れています。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • その他欧州
  • アジア太平洋
  • その他の地域

第4章 競合

目次
Product Code: MCP33449

Global Antibody Discovery Market to Reach US$3.3 Billion by 2030

The global market for Antibody Discovery estimated at US$1.9 Billion in the year 2024, is expected to reach US$3.3 Billion by 2030, growing at a CAGR of 9.8% over the analysis period 2024-2030. Monoclonal Antibody, one of the segments analyzed in the report, is expected to record a 9.3% CAGR and reach US$2.0 Billion by the end of the analysis period. Growth in the Polyclonal Antibody segment is estimated at 10.9% CAGR over the analysis period.

The U.S. Market is Estimated at US$500.0 Million While China is Forecast to Grow at 9.5% CAGR

The Antibody Discovery market in the U.S. is estimated at US$500.0 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$530.7 Million by the year 2030 trailing a CAGR of 9.5% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 8.9% and 8.4% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 7.9% CAGR.

Global Antibody Discovery Market - Key Trends & Drivers Summarized

Why Is Antibody Discovery at the Forefront of Next-Generation Therapeutic Development?

Antibody discovery is emerging as a cornerstone of modern drug development, driven by the escalating demand for targeted therapies across oncology, autoimmune disorders, infectious diseases, and rare conditions. Monoclonal antibodies (mAbs), bispecific antibodies, and antibody-drug conjugates (ADCs) are transforming clinical outcomes through their high specificity, tunable pharmacokinetics, and ability to engage or inhibit precise molecular targets. The discovery phase-encompassing target identification, antibody generation, screening, and lead optimization-is critical to ensuring downstream therapeutic efficacy, safety, and commercial viability. As biopharmaceutical pipelines increasingly prioritize biologics over small molecules, antibody discovery is becoming an indispensable gateway to innovation.

A significant driver of this trend is the surge in demand for personalized medicine and immunotherapy, where antibody-based therapeutics are used to modulate immune response, block disease-associated pathways, or deliver cytotoxic payloads directly to tumor cells. The urgency created by the COVID-19 pandemic further underscored the importance of rapid antibody discovery, as neutralizing antibodies became pivotal in the therapeutic and diagnostic response to SARS-CoV-2. Global interest in therapeutic antibodies is prompting pharmaceutical and biotech firms to accelerate discovery programs using faster, more predictive, and less immunogenic methods. As the market shifts from traditional hybridoma techniques to humanized platforms and next-gen in silico approaches, antibody discovery is positioned at the heart of biopharma R&D strategies worldwide.

How Are Technological Innovations Accelerating Discovery Timelines and Improving Lead Quality?

Cutting-edge technologies are reshaping every stage of the antibody discovery process, enabling faster identification of high-affinity, developable antibodies with favorable safety and manufacturability profiles. Phage display and yeast display platforms have largely replaced traditional hybridoma-based generation, offering vast diversity libraries and rapid selection capabilities. More recently, microfluidics, single B-cell screening, and high-throughput sequencing have revolutionized early-stage discovery by capturing naturally occurring antibody repertoires from immunized animals or convalescent human donors. These tools enable the isolation of rare, highly potent antibodies that would otherwise go undetected through conventional methods.

Computational biology and AI-driven design are also transforming the discovery pipeline by predicting binding affinity, stability, immunogenicity, and epitope specificity in silico. Machine learning algorithms are being trained on large antibody datasets to accelerate lead optimization, reduce experimental trial-and-error, and improve success rates in later development phases. Humanization techniques-ranging from chimerization to full deimmunization-are being refined to enhance safety and reduce rejection risk. Additionally, CRISPR/Cas9 and transgenic animal models are being leveraged to generate fully human antibodies with precise specificity. These technology integrations are enabling rapid, scalable, and cost-efficient antibody discovery workflows that meet the high standards of regulatory and therapeutic rigor.

Where Is Market Demand Rising and Which Therapeutic Areas Are Driving Discovery Investment?

Market demand for antibody discovery services and platforms is rising sharply across North America, Europe, and Asia-Pacific, where biopharma companies, academic labs, and contract research organizations (CROs) are intensifying efforts to expand antibody-based pipelines. The U.S. leads in therapeutic antibody development, backed by significant biotech investment, advanced research infrastructure, and regulatory support for expedited biologic approvals. Europe, particularly Germany, Switzerland, and the U.K., is seeing strong growth in CRO-based discovery partnerships and academic spinouts. Meanwhile, Asia-Pacific-especially China, South Korea, and Japan-is becoming a major hub for antibody innovation, fueled by state-backed biotech programs, growing clinical trial activity, and rapid commercialization strategies.

Oncology remains the largest and fastest-growing therapeutic segment for antibody discovery, accounting for the majority of pipeline activity in monoclonal and bispecific antibodies. Immuno-oncology applications, such as checkpoint inhibitors and T-cell engagers, are expanding rapidly with significant investment in PD-1/PD-L1, CTLA-4, CD3, and CD20 targets. Autoimmune and inflammatory diseases-including rheumatoid arthritis, psoriasis, and Crohn’s disease-also represent major discovery areas, with antibody candidates aimed at cytokines and immune receptors such as IL-6, TNF-alpha, and IL-17. Infectious disease research continues to drive antibody discovery in the wake of COVID-19, with new programs targeting HIV, RSV, and influenza. Rare and neurological diseases, including ALS, Alzheimer’s, and neuromyelitis optica, are emerging as high-value niches for precision antibody therapies. These diverse and expanding indications are propelling sustained investment and innovation in antibody discovery workflows across sectors.

What Is Fueling the Growth of the Global Antibody Discovery Market?

The growth in the antibody discovery market is driven by several factors, including the rising prevalence of chronic and rare diseases, expansion of biologics pipelines, and breakthroughs in molecular screening and AI-assisted drug design. A central driver is the therapeutic success of antibodies already in the market-such as trastuzumab, adalimumab, and pembrolizumab-which continue to demonstrate the clinical and commercial potential of antibody-based drugs. The robust deal activity between pharmaceutical giants and antibody discovery specialists is further catalyzing growth, as companies seek early access to differentiated platforms and promising candidates.

Increased outsourcing by biotech startups and mid-sized firms is also fueling market demand for discovery-as-a-service models, where CROs and specialized technology vendors provide end-to-end discovery capabilities from antigen design to humanized lead delivery. Advances in automation, sequencing, and data analytics are lowering the cost per discovery while improving success predictability, making antibody R&D more accessible to smaller players. Moreover, government and institutional funding for pandemic preparedness, cancer immunotherapy, and biosimilar development are boosting both public and private sector involvement. As antibody therapeutics become increasingly central to precision medicine and immune modulation, a crucial question emerges: Can antibody discovery platforms keep pace with the clinical complexity and specificity required for next-generation, globally accessible biologic treatments?

SCOPE OF STUDY:

The report analyzes the Antibody Discovery market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Antibody Type (Monoclonal, Polyclonal, Other Antibody Types); Service (Phage Display, Hybridoma, Other Services); End-Use (Pharmaceutical & Biotechnology Companies, Research Laboratories, Other End-Uses)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; and Rest of Europe); Asia-Pacific; Rest of World.

Select Competitors (Total 41 Featured) -

  • Abcam plc
  • AbCellera Biologics Inc.
  • Ablexis, LLC
  • Adimab LLC
  • Akeso Biopharma
  • Biocytogen Pharmaceuticals Co., Ltd.
  • Bruker Corporation
  • Charles River Laboratories
  • ChemPartner
  • Creative Biolabs
  • Danaher Corporation
  • Eurofins Scientific
  • Evotec SE
  • FairJourney Biologics S.A.
  • Genmab A/S
  • GenScript Biotech Corporation
  • Harbour BioMed
  • Icosagen AS
  • ImmunoPrecise Antibodies Ltd.
  • Isogenica Ltd.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by artificially increasing the COGS, reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

We are diligently following expert opinions of leading Chief Economists (14,949), Think Tanks (62), Trade & Industry bodies (171) worldwide, as they assess impact and address new market realities for their ecosystems. Experts and economists from every major country are tracked for their opinions on tariffs and how they will impact their countries.

We expect this chaos to play out over the next 2-3 months and a new world order is established with more clarity. We are tracking these developments on a real time basis.

As we release this report, U.S. Trade Representatives are pushing their counterparts in 183 countries for an early closure to bilateral tariff negotiations. Most of the major trading partners also have initiated trade agreements with other key trading nations, outside of those in the works with the United States. We are tracking such secondary fallouts as supply chains shift.

To our valued clients, we say, we have your back. We will present a simplified market reassessment by incorporating these changes!

APRIL 2025: NEGOTIATION PHASE

Our April release addresses the impact of tariffs on the overall global market and presents market adjustments by geography. Our trajectories are based on historic data and evolving market impacting factors.

JULY 2025 FINAL TARIFF RESET

Complimentary Update: Our clients will also receive a complimentary update in July after a final reset is announced between nations. The final updated version incorporates clearly defined Tariff Impact Analyses.

Reciprocal and Bilateral Trade & Tariff Impact Analyses:

USA <> CHINA <> MEXICO <> CANADA <> EU <> JAPAN <> INDIA <> 176 OTHER COUNTRIES.

Leading Economists - Our knowledge base tracks 14,949 economists including a select group of most influential Chief Economists of nations, think tanks, trade and industry bodies, big enterprises, and domain experts who are sharing views on the fallout of this unprecedented paradigm shift in the global econometric landscape. Most of our 16,491+ reports have incorporated this two-stage release schedule based on milestones.

COMPLIMENTARY PREVIEW

Contact your sales agent to request an online 300+ page complimentary preview of this research project. Our preview will present full stack sources, and validated domain expert data transcripts. Deep dive into our interactive data-driven online platform.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Antibody Discovery - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Demand for Precision Biologics Spurs Innovation Across the Antibody Discovery Landscape
    • AI-Driven Screening Platforms Shorten Discovery Timelines for Therapeutic Antibodies
    • Next-Generation Sequencing and Single-Cell Tools Redefine Antibody Target Identification
    • CRO Partnerships Accelerate Outsourced Antibody Discovery Among Biopharma Firms
    • Oncology and Autoimmune Therapies Dominate the Clinical Focus of Antibody Discovery Pipelines
    • Transgenic Animal Models Expand the Scope of Novel Antibody Generation
    • Bispecific and Monoclonal Advances Unlock Complex Disease Targeting in Antibody Discovery
    • Data Integration Across Platforms Enhances Efficiency in Antibody Optimization
    • Collaborations with Academia Infuse Innovation into Antibody Discovery Frameworks
    • Expiry of Biologic Patents Opens New Pathways for Biosimilar Antibody Development
    • Regulatory Support for First-in-Class Biologics Encourages Bold Innovation in Discovery
    • End-to-End Platform Integration Strengthens the Commercial Value Chain in Antibody Discovery
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Antibody Discovery Market Analysis of Annual Sales in US$ Thousand for Years 2015 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Antibody Discovery by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Antibody Discovery by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 4: World 15-Year Perspective for Antibody Discovery by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2015, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Monoclonal by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Monoclonal by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 7: World 15-Year Perspective for Monoclonal by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Polyclonal by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Polyclonal by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 10: World 15-Year Perspective for Polyclonal by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Other Antibody Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Other Antibody Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 13: World 15-Year Perspective for Other Antibody Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Phage Display by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Phage Display by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 16: World 15-Year Perspective for Phage Display by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Hybridoma by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Hybridoma by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 19: World 15-Year Perspective for Hybridoma by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Other Services by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Other Services by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 22: World 15-Year Perspective for Other Services by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Pharmaceutical & Biotechnology Companies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Pharmaceutical & Biotechnology Companies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 25: World 15-Year Perspective for Pharmaceutical & Biotechnology Companies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Research Laboratories by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 27: World Historic Review for Research Laboratories by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 28: World 15-Year Perspective for Research Laboratories by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 29: World Recent Past, Current & Future Analysis for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 30: World Historic Review for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 31: World 15-Year Perspective for Other End-Uses by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Antibody Discovery Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 32: USA Recent Past, Current & Future Analysis for Antibody Discovery by Antibody Type - Monoclonal, Polyclonal and Other Antibody Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 33: USA Historic Review for Antibody Discovery by Antibody Type - Monoclonal, Polyclonal and Other Antibody Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 34: USA 15-Year Perspective for Antibody Discovery by Antibody Type - Percentage Breakdown of Value Sales for Monoclonal, Polyclonal and Other Antibody Types for the Years 2015, 2025 & 2030
    • TABLE 35: USA Recent Past, Current & Future Analysis for Antibody Discovery by Service - Phage Display, Hybridoma and Other Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 36: USA Historic Review for Antibody Discovery by Service - Phage Display, Hybridoma and Other Services Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 37: USA 15-Year Perspective for Antibody Discovery by Service - Percentage Breakdown of Value Sales for Phage Display, Hybridoma and Other Services for the Years 2015, 2025 & 2030
    • TABLE 38: USA Recent Past, Current & Future Analysis for Antibody Discovery by End-Use - Pharmaceutical & Biotechnology Companies, Research Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 39: USA Historic Review for Antibody Discovery by End-Use - Pharmaceutical & Biotechnology Companies, Research Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 40: USA 15-Year Perspective for Antibody Discovery by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical & Biotechnology Companies, Research Laboratories and Other End-Uses for the Years 2015, 2025 & 2030
  • CANADA
    • TABLE 41: Canada Recent Past, Current & Future Analysis for Antibody Discovery by Antibody Type - Monoclonal, Polyclonal and Other Antibody Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 42: Canada Historic Review for Antibody Discovery by Antibody Type - Monoclonal, Polyclonal and Other Antibody Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 43: Canada 15-Year Perspective for Antibody Discovery by Antibody Type - Percentage Breakdown of Value Sales for Monoclonal, Polyclonal and Other Antibody Types for the Years 2015, 2025 & 2030
    • TABLE 44: Canada Recent Past, Current & Future Analysis for Antibody Discovery by Service - Phage Display, Hybridoma and Other Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 45: Canada Historic Review for Antibody Discovery by Service - Phage Display, Hybridoma and Other Services Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 46: Canada 15-Year Perspective for Antibody Discovery by Service - Percentage Breakdown of Value Sales for Phage Display, Hybridoma and Other Services for the Years 2015, 2025 & 2030
    • TABLE 47: Canada Recent Past, Current & Future Analysis for Antibody Discovery by End-Use - Pharmaceutical & Biotechnology Companies, Research Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 48: Canada Historic Review for Antibody Discovery by End-Use - Pharmaceutical & Biotechnology Companies, Research Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 49: Canada 15-Year Perspective for Antibody Discovery by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical & Biotechnology Companies, Research Laboratories and Other End-Uses for the Years 2015, 2025 & 2030
  • JAPAN
    • Antibody Discovery Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 50: Japan Recent Past, Current & Future Analysis for Antibody Discovery by Antibody Type - Monoclonal, Polyclonal and Other Antibody Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 51: Japan Historic Review for Antibody Discovery by Antibody Type - Monoclonal, Polyclonal and Other Antibody Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 52: Japan 15-Year Perspective for Antibody Discovery by Antibody Type - Percentage Breakdown of Value Sales for Monoclonal, Polyclonal and Other Antibody Types for the Years 2015, 2025 & 2030
    • TABLE 53: Japan Recent Past, Current & Future Analysis for Antibody Discovery by Service - Phage Display, Hybridoma and Other Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 54: Japan Historic Review for Antibody Discovery by Service - Phage Display, Hybridoma and Other Services Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 55: Japan 15-Year Perspective for Antibody Discovery by Service - Percentage Breakdown of Value Sales for Phage Display, Hybridoma and Other Services for the Years 2015, 2025 & 2030
    • TABLE 56: Japan Recent Past, Current & Future Analysis for Antibody Discovery by End-Use - Pharmaceutical & Biotechnology Companies, Research Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 57: Japan Historic Review for Antibody Discovery by End-Use - Pharmaceutical & Biotechnology Companies, Research Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 58: Japan 15-Year Perspective for Antibody Discovery by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical & Biotechnology Companies, Research Laboratories and Other End-Uses for the Years 2015, 2025 & 2030
  • CHINA
    • Antibody Discovery Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 59: China Recent Past, Current & Future Analysis for Antibody Discovery by Antibody Type - Monoclonal, Polyclonal and Other Antibody Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 60: China Historic Review for Antibody Discovery by Antibody Type - Monoclonal, Polyclonal and Other Antibody Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 61: China 15-Year Perspective for Antibody Discovery by Antibody Type - Percentage Breakdown of Value Sales for Monoclonal, Polyclonal and Other Antibody Types for the Years 2015, 2025 & 2030
    • TABLE 62: China Recent Past, Current & Future Analysis for Antibody Discovery by Service - Phage Display, Hybridoma and Other Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 63: China Historic Review for Antibody Discovery by Service - Phage Display, Hybridoma and Other Services Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 64: China 15-Year Perspective for Antibody Discovery by Service - Percentage Breakdown of Value Sales for Phage Display, Hybridoma and Other Services for the Years 2015, 2025 & 2030
    • TABLE 65: China Recent Past, Current & Future Analysis for Antibody Discovery by End-Use - Pharmaceutical & Biotechnology Companies, Research Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 66: China Historic Review for Antibody Discovery by End-Use - Pharmaceutical & Biotechnology Companies, Research Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 67: China 15-Year Perspective for Antibody Discovery by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical & Biotechnology Companies, Research Laboratories and Other End-Uses for the Years 2015, 2025 & 2030
  • EUROPE
    • Antibody Discovery Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 68: Europe Recent Past, Current & Future Analysis for Antibody Discovery by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 69: Europe Historic Review for Antibody Discovery by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 70: Europe 15-Year Perspective for Antibody Discovery by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2015, 2025 & 2030
    • TABLE 71: Europe Recent Past, Current & Future Analysis for Antibody Discovery by Antibody Type - Monoclonal, Polyclonal and Other Antibody Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 72: Europe Historic Review for Antibody Discovery by Antibody Type - Monoclonal, Polyclonal and Other Antibody Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 73: Europe 15-Year Perspective for Antibody Discovery by Antibody Type - Percentage Breakdown of Value Sales for Monoclonal, Polyclonal and Other Antibody Types for the Years 2015, 2025 & 2030
    • TABLE 74: Europe Recent Past, Current & Future Analysis for Antibody Discovery by Service - Phage Display, Hybridoma and Other Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 75: Europe Historic Review for Antibody Discovery by Service - Phage Display, Hybridoma and Other Services Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 76: Europe 15-Year Perspective for Antibody Discovery by Service - Percentage Breakdown of Value Sales for Phage Display, Hybridoma and Other Services for the Years 2015, 2025 & 2030
    • TABLE 77: Europe Recent Past, Current & Future Analysis for Antibody Discovery by End-Use - Pharmaceutical & Biotechnology Companies, Research Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 78: Europe Historic Review for Antibody Discovery by End-Use - Pharmaceutical & Biotechnology Companies, Research Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 79: Europe 15-Year Perspective for Antibody Discovery by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical & Biotechnology Companies, Research Laboratories and Other End-Uses for the Years 2015, 2025 & 2030
  • FRANCE
    • Antibody Discovery Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 80: France Recent Past, Current & Future Analysis for Antibody Discovery by Antibody Type - Monoclonal, Polyclonal and Other Antibody Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 81: France Historic Review for Antibody Discovery by Antibody Type - Monoclonal, Polyclonal and Other Antibody Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 82: France 15-Year Perspective for Antibody Discovery by Antibody Type - Percentage Breakdown of Value Sales for Monoclonal, Polyclonal and Other Antibody Types for the Years 2015, 2025 & 2030
    • TABLE 83: France Recent Past, Current & Future Analysis for Antibody Discovery by Service - Phage Display, Hybridoma and Other Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 84: France Historic Review for Antibody Discovery by Service - Phage Display, Hybridoma and Other Services Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 85: France 15-Year Perspective for Antibody Discovery by Service - Percentage Breakdown of Value Sales for Phage Display, Hybridoma and Other Services for the Years 2015, 2025 & 2030
    • TABLE 86: France Recent Past, Current & Future Analysis for Antibody Discovery by End-Use - Pharmaceutical & Biotechnology Companies, Research Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 87: France Historic Review for Antibody Discovery by End-Use - Pharmaceutical & Biotechnology Companies, Research Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 88: France 15-Year Perspective for Antibody Discovery by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical & Biotechnology Companies, Research Laboratories and Other End-Uses for the Years 2015, 2025 & 2030
  • GERMANY
    • Antibody Discovery Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 89: Germany Recent Past, Current & Future Analysis for Antibody Discovery by Antibody Type - Monoclonal, Polyclonal and Other Antibody Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 90: Germany Historic Review for Antibody Discovery by Antibody Type - Monoclonal, Polyclonal and Other Antibody Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 91: Germany 15-Year Perspective for Antibody Discovery by Antibody Type - Percentage Breakdown of Value Sales for Monoclonal, Polyclonal and Other Antibody Types for the Years 2015, 2025 & 2030
    • TABLE 92: Germany Recent Past, Current & Future Analysis for Antibody Discovery by Service - Phage Display, Hybridoma and Other Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Germany Historic Review for Antibody Discovery by Service - Phage Display, Hybridoma and Other Services Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 94: Germany 15-Year Perspective for Antibody Discovery by Service - Percentage Breakdown of Value Sales for Phage Display, Hybridoma and Other Services for the Years 2015, 2025 & 2030
    • TABLE 95: Germany Recent Past, Current & Future Analysis for Antibody Discovery by End-Use - Pharmaceutical & Biotechnology Companies, Research Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 96: Germany Historic Review for Antibody Discovery by End-Use - Pharmaceutical & Biotechnology Companies, Research Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 97: Germany 15-Year Perspective for Antibody Discovery by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical & Biotechnology Companies, Research Laboratories and Other End-Uses for the Years 2015, 2025 & 2030
  • ITALY
    • TABLE 98: Italy Recent Past, Current & Future Analysis for Antibody Discovery by Antibody Type - Monoclonal, Polyclonal and Other Antibody Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Italy Historic Review for Antibody Discovery by Antibody Type - Monoclonal, Polyclonal and Other Antibody Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 100: Italy 15-Year Perspective for Antibody Discovery by Antibody Type - Percentage Breakdown of Value Sales for Monoclonal, Polyclonal and Other Antibody Types for the Years 2015, 2025 & 2030
    • TABLE 101: Italy Recent Past, Current & Future Analysis for Antibody Discovery by Service - Phage Display, Hybridoma and Other Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 102: Italy Historic Review for Antibody Discovery by Service - Phage Display, Hybridoma and Other Services Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 103: Italy 15-Year Perspective for Antibody Discovery by Service - Percentage Breakdown of Value Sales for Phage Display, Hybridoma and Other Services for the Years 2015, 2025 & 2030
    • TABLE 104: Italy Recent Past, Current & Future Analysis for Antibody Discovery by End-Use - Pharmaceutical & Biotechnology Companies, Research Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 105: Italy Historic Review for Antibody Discovery by End-Use - Pharmaceutical & Biotechnology Companies, Research Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 106: Italy 15-Year Perspective for Antibody Discovery by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical & Biotechnology Companies, Research Laboratories and Other End-Uses for the Years 2015, 2025 & 2030
  • UNITED KINGDOM
    • Antibody Discovery Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 107: UK Recent Past, Current & Future Analysis for Antibody Discovery by Antibody Type - Monoclonal, Polyclonal and Other Antibody Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 108: UK Historic Review for Antibody Discovery by Antibody Type - Monoclonal, Polyclonal and Other Antibody Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 109: UK 15-Year Perspective for Antibody Discovery by Antibody Type - Percentage Breakdown of Value Sales for Monoclonal, Polyclonal and Other Antibody Types for the Years 2015, 2025 & 2030
    • TABLE 110: UK Recent Past, Current & Future Analysis for Antibody Discovery by Service - Phage Display, Hybridoma and Other Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 111: UK Historic Review for Antibody Discovery by Service - Phage Display, Hybridoma and Other Services Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 112: UK 15-Year Perspective for Antibody Discovery by Service - Percentage Breakdown of Value Sales for Phage Display, Hybridoma and Other Services for the Years 2015, 2025 & 2030
    • TABLE 113: UK Recent Past, Current & Future Analysis for Antibody Discovery by End-Use - Pharmaceutical & Biotechnology Companies, Research Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 114: UK Historic Review for Antibody Discovery by End-Use - Pharmaceutical & Biotechnology Companies, Research Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 115: UK 15-Year Perspective for Antibody Discovery by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical & Biotechnology Companies, Research Laboratories and Other End-Uses for the Years 2015, 2025 & 2030
  • REST OF EUROPE
    • TABLE 116: Rest of Europe Recent Past, Current & Future Analysis for Antibody Discovery by Antibody Type - Monoclonal, Polyclonal and Other Antibody Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 117: Rest of Europe Historic Review for Antibody Discovery by Antibody Type - Monoclonal, Polyclonal and Other Antibody Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 118: Rest of Europe 15-Year Perspective for Antibody Discovery by Antibody Type - Percentage Breakdown of Value Sales for Monoclonal, Polyclonal and Other Antibody Types for the Years 2015, 2025 & 2030
    • TABLE 119: Rest of Europe Recent Past, Current & Future Analysis for Antibody Discovery by Service - Phage Display, Hybridoma and Other Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 120: Rest of Europe Historic Review for Antibody Discovery by Service - Phage Display, Hybridoma and Other Services Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 121: Rest of Europe 15-Year Perspective for Antibody Discovery by Service - Percentage Breakdown of Value Sales for Phage Display, Hybridoma and Other Services for the Years 2015, 2025 & 2030
    • TABLE 122: Rest of Europe Recent Past, Current & Future Analysis for Antibody Discovery by End-Use - Pharmaceutical & Biotechnology Companies, Research Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 123: Rest of Europe Historic Review for Antibody Discovery by End-Use - Pharmaceutical & Biotechnology Companies, Research Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 124: Rest of Europe 15-Year Perspective for Antibody Discovery by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical & Biotechnology Companies, Research Laboratories and Other End-Uses for the Years 2015, 2025 & 2030
  • ASIA-PACIFIC
    • Antibody Discovery Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 125: Asia-Pacific Recent Past, Current & Future Analysis for Antibody Discovery by Antibody Type - Monoclonal, Polyclonal and Other Antibody Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 126: Asia-Pacific Historic Review for Antibody Discovery by Antibody Type - Monoclonal, Polyclonal and Other Antibody Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 127: Asia-Pacific 15-Year Perspective for Antibody Discovery by Antibody Type - Percentage Breakdown of Value Sales for Monoclonal, Polyclonal and Other Antibody Types for the Years 2015, 2025 & 2030
    • TABLE 128: Asia-Pacific Recent Past, Current & Future Analysis for Antibody Discovery by Service - Phage Display, Hybridoma and Other Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 129: Asia-Pacific Historic Review for Antibody Discovery by Service - Phage Display, Hybridoma and Other Services Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 130: Asia-Pacific 15-Year Perspective for Antibody Discovery by Service - Percentage Breakdown of Value Sales for Phage Display, Hybridoma and Other Services for the Years 2015, 2025 & 2030
    • TABLE 131: Asia-Pacific Recent Past, Current & Future Analysis for Antibody Discovery by End-Use - Pharmaceutical & Biotechnology Companies, Research Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 132: Asia-Pacific Historic Review for Antibody Discovery by End-Use - Pharmaceutical & Biotechnology Companies, Research Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 133: Asia-Pacific 15-Year Perspective for Antibody Discovery by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical & Biotechnology Companies, Research Laboratories and Other End-Uses for the Years 2015, 2025 & 2030
  • REST OF WORLD
    • TABLE 134: Rest of World Recent Past, Current & Future Analysis for Antibody Discovery by Antibody Type - Monoclonal, Polyclonal and Other Antibody Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 135: Rest of World Historic Review for Antibody Discovery by Antibody Type - Monoclonal, Polyclonal and Other Antibody Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 136: Rest of World 15-Year Perspective for Antibody Discovery by Antibody Type - Percentage Breakdown of Value Sales for Monoclonal, Polyclonal and Other Antibody Types for the Years 2015, 2025 & 2030
    • TABLE 137: Rest of World Recent Past, Current & Future Analysis for Antibody Discovery by Service - Phage Display, Hybridoma and Other Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 138: Rest of World Historic Review for Antibody Discovery by Service - Phage Display, Hybridoma and Other Services Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 139: Rest of World 15-Year Perspective for Antibody Discovery by Service - Percentage Breakdown of Value Sales for Phage Display, Hybridoma and Other Services for the Years 2015, 2025 & 2030
    • TABLE 140: Rest of World Recent Past, Current & Future Analysis for Antibody Discovery by End-Use - Pharmaceutical & Biotechnology Companies, Research Laboratories and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 141: Rest of World Historic Review for Antibody Discovery by End-Use - Pharmaceutical & Biotechnology Companies, Research Laboratories and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 142: Rest of World 15-Year Perspective for Antibody Discovery by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical & Biotechnology Companies, Research Laboratories and Other End-Uses for the Years 2015, 2025 & 2030

IV. COMPETITION